		ICIVIJE DISC	LOSURE FORIVI				
Da	te:2022-07-26						
			gene signature for the prognosis of ovarian cancer	_			
	Manuscript number (if known):						
In <sup>1</sup>	the interest of transparency	, we ask you to disclose a	Il relationships/activities/interests listed below that are	<b>)</b>			
		•	eans any relation with for-profit or not-for-profit third				
			of the manuscript. Disclosure represents a commitment	t			
-		<del>-</del>	. If you are in doubt about whether to list a				
	ationship/activity/interest,						
Th	e following questions apply	to the author's relationsh	ips/activities/interests as they relate to the current				
ma	nuscript only.						
Th	e author's relationships/act	ivities/interests should be	defined broadly. For example, if your manuscript perta	ains			
to	the epidemiology of hypert	ension, you should declare	e all relationships with manufacturers of antihypertensi	ive			
me	edication, even if that medic	cation is not mentioned in	the manuscript.				
In	item #1 below, report all su	pport for the work report	ed in this manuscript without time limit. For all other it	ems,			
the	e time frame for disclosure i	s the past 36 months.					
		Name all entities with	Specifications/Comments				
		whom you have this	(e.g., if payments were made to you or to your				
		relationship or indicate	institution)				
		none (add rows as	montation,				
		needed)					
		Time frame: Since the initia	al planning of the work				
1	All support for the present	XNone					
	manuscript (e.g., funding,						
	provision of study materials,						

Time frame: past 36 months

\_X\_\_None

\_None

\_X\_\_None

medical writing, article processing charges, etc.)

No time limit for this item.

Grants or contracts from

in item #1 above).

Consulting fees

Royalties or licenses

any entity (if not indicated

2

3

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	
Ple	ase summarize the above co	onflict of interest in the fol	owing box:
	No conflict of interest with this	manuscript	

Date	e:2022-07-26		
	r Name:		
Mar	nuscript Title:Identifica	tion and validation of a 9-g	gene signature for the prognosis of ovarian cancer
Mar	nuscript number (if known)	:	
rela part to ti rela	ted to the content of your lies whose interests may be ransparency and does not a tionship/activity/interest,	manuscript. "Related" me e affected by the content on necessarily indicate a bias. it is preferable that you do	
		to the author's relationship	ips/activities/interests as they relate to the <u>current</u>
IIIai	nuscript only.		
to ti med In it	ne epidemiology of hyperto lication, even if that medic	ension, you should declare ation is not mentioned in pport for the work reporte	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.  ed in this manuscript without time limit. For all other items
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	I planning of the work
	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
	to time initial time in the in-		
		Time frame: past	t 36 months
	Grants or contracts from	X None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_XNone	
L	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	
Ple	ase summarize the above co	onflict of interest in the fol	owing box:
	No conflict of interest with this	manuscript	

	te:2022-07-26			
	ur Name:Haikเ			
Ma	nuscript Title:Identificat	tion and validation of a 9-g	gene signature for the prognosis of ovarian cancer	
Ma	nuscript number (if known)	:		
relator relator me	ated to the content of your ries whose interests may be transparency and does not eationship/activity/interest, e following questions apply muscript only.  e author's relationships/activite epidemiology of hypertedication, even if that medication.	manuscript. "Related" mede affected by the content of necessarily indicate a bias. It is preferable that you do to the author's relationship ivities/interests should be ension, you should declare eation is not mentioned in the poort for the work reported.	ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive	
		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			planning of the work	
1	All support for the present	XNone		
	manuscript (e.g., funding, provision of study materials,			
	medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			
	No time limit for this item.			
	No time limit for this item.			
	No time limit for this item.	Time frame: past	36 months	
2	No time limit for this item.  Grants or contracts from	Time frame: past	36 months	
2			36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).		36 months	
2	Grants or contracts from any entity (if not indicated		36 months	
	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	36 months	
	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	36 months	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	
Ple	ase summarize the above co	onflict of interest in the fol	owing box:
	No conflict of interest with this	manuscript	

Date	e:2022-07-26		
	r Name:		
Mar	nuscript Title:Identificat	tion and validation of a 9-	gene signature for the prognosis of ovarian cancer
Mar	nuscript number (if known)	):	
rela part to ti rela	ted to the content of your ies whose interests may be ransparency and does not a tionship/activity/interest,	manuscript. "Related" me e affected by the content on necessarily indicate a bias. it is preferable that you do	
		to the author's relationship	ips/activities/interests as they relate to the <u>current</u>
mar	uscript only.		
to tl med In it	ne epidemiology of hyperto lication, even if that medic	ension, you should declare cation is not mentioned in pport for the work reporte	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.  ed in this manuscript without time limit. For all other items
		•	
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate none (add rows as	institution)
		needed)	
		Time frame: Since the initia	l planning of the work
	All support for the present	X None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	t 36 months
	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).	V N	
3	Royalties or licenses	_XNone	
	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	
Ple	ase summarize the above co	onflict of interest in the fol	owing box:
	No conflict of interest with this	manuscript	

Da	te:2022-07-26			
Yo	ur Name:	Chunming Gu		
			ene signature for the prognosis of ovarian cancer	
	nuscript number (if known)			
rela par to	ated to the content of your rties whose interests may b	manuscript. "Related" mea e affected by the content on necessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.	
	e following questions apply nuscript only.	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>	
to		ension, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.	
	tem #1 below, report all su e time frame for disclosure i		d in this manuscript without time limit. For all other item	ıs,
	· -	Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)	ıs,
	· -	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	is,
the	e time frame for disclosure i	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)	ıs,
the	e time frame for disclosure i	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	ıs,
	All support for the present manuscript (e.g., funding,	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)	is,
the	e time frame for disclosure i	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)	is,
the	All support for the present manuscript (e.g., funding, provision of study materials,	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)	is,
the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)	is,
the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)	is,
the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initiaXNone	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work	ıs,
the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initiaXNone	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work	ıs,
the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initiaXNone	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work	ıs,
the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initiaXNone	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work	ıs,
11	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia XNone  Time frame: pastXNone	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work	is,
the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initiaXNone	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work	is,

Consulting fees

\_X\_\_None

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	
Ple	ase summarize the above co	onflict of interest in the fol	owing box:
	No conflict of interest with this	manuscript	

Da	te:2022-07-26		
Yo	ur Name:	Weifeng Wei	
			gene signature for the prognosis of ovarian cancer
rel par to rel	ated to the content of your ries whose interests may be transparency and does not ationship/activity/interest,	manuscript. "Related" me e affected by the content on necessarily indicate a bias it is preferable that you do	I relationships/activities/interests listed below that are cans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a o so.
ma	nuscript only.		
to me	the epidemiology of hypertodication, even if that medic	ension, you should declare ation is not mentioned in pport for the work reporte s the past 36 months.	ed in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate none (add rows as	institution)
		needed)	
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	XNone	
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	t 36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
_	in item #1 above).	V N	
3	Royalties or licenses	_XNone	

Consulting fees

\_X\_\_None

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	
Ple	ase summarize the above co	onflict of interest in the fol	owing box:
	No conflict of interest with this	manuscript	